Nisa Investment Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Nisa Investment Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	–	–	2921
2023 Q1	$0	Hold	100	–	–	﹤0.01%	2824
2022 Q4	$1K	Buy	+100	New	+$546	﹤0.01%	2566

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Nisa Investment Advisors's CTIC Position: Q2 2023 in Review

Nisa Investment Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 100 shares.

Nisa Investment Advisors first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $1K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Nisa Investment Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Nisa Investment Advisors sold 100 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023.
Nisa Investment Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Nisa Investment Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $1K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Nisa Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.